Risankizumab Therapy for Moderate-to-Severe Psoriasis-A Multi-Center, Long-Term, Real-Life Study from Poland

• Published in: Journal of clinical medicine Vol. 12; no. 4; p. 1675
• Main Authors: Adamczyk, Michał, Bartosińska, Joanna, Raczkiewicz, Dorota, Adamska, Kinga, Adamski, Zygmunt, Czubek, Maria, Kręcisz, Beata, Kłujszo, Elżbieta, Lesiak, Aleksandra, Narbutt, Joanna, Noweta, Marcin, Owczarczyk-Saczonek, Agnieszka, Owczarek, Witold, Reich, Adam, Samotij, Dominik, Siekierko, Aleksandra, Szczęch, Justyna, Walecka, Irena, Ciechanowicz, Piotr, Woźniacka, Anna, Liszewska, Agata, Krasowska, Dorota
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.02.2023; MDPI
• Subjects: biologic treatment; Body mass index; Cardiovascular disease; Clinical medicine; Clinical trials; Development and progression; Diagnosis; Drug dosages; Drug therapy; Metabolism; Monoclonal antibodies; Psoriasis; real-life experience; risankizumab; Skin; systemic treatment; Poland; real-life experience; biologic treatment; systemic treatment; psoriasis; risankizumab
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12041675

The present multi-center, long-term, real-life study made an attempt to assess the efficacy of risankizumab in the treatment of moderate-to-severe plaque psoriasis. The study comprised 185 patients from 10 Polish dermatologic departments undergoing risankizumab treatment. The disease severity was measured using the Psoriasis Area and Severity Index (PASI) before the start of the risankizumab treatment and next at the defined timepoints, i.e., 4, 16, 28, 40, 52 and 96 weeks of treatment. The percentage of patients achieving PASI90 and PASI100 responses as well as the PASI percentage decrease at the defined timepoints were calculated, and correlations with clinical characteristics and therapeutic effect were analyzed. The number of patients evaluated at the defined timepoints was: 136, 145, 100, 93, 62, and 22 at 4, 16, 28, 40, 52 and 96 weeks of treatment, respectively. At 4, 16, 28, 40, 52 and 96 weeks, the PASI90 response was achieved in 13.2%, 81.4%, 87.0%, 86.0%, 88.7% and 81.8% of patients, whereas the PASI100 response was achieved in 2.9%, 53.1%, 67.0%, 68.8%, 71.0% and 68.2% of patients, respectively. Our study revealed a significant negative correlation between a decrease in the PASI and the presence of psoriatic arthritis as well as the patient's age and duration of psoriasis at several timepoints throughout the observation period.